| Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals N Fandos, V Pérez-Grijalba, P Pesini, S Olmos, M Bossa, VL Villemagne, ... Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 8, 179-187, 2017 | 179 | 2017 |
| Total Aβ42/Aβ40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis JD Doecke, V Pérez-Grijalba, N Fandos, C Fowler, VL Villemagne, ... Neurology 94 (15), e1580-e1591, 2020 | 124 | 2020 |
| Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease R Perez-Gonzalez, C Pascual, D Antequera, M Bolos, M Redondo, ... Neurobiology of aging 34 (9), 2133-2145, 2013 | 101 | 2013 |
| Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo … AM Lacosta, M Pascual-Lucas, P Pesini, D Casabona, V Pérez-Grijalba, ... Alzheimer's research & therapy 10, 1-13, 2018 | 88 | 2018 |
| Plasma Aβ42/40 ratio detects early stages of Alzheimer’s disease and correlates with CSF and neuroimaging biomarkers in the AB255 study V Perez-Grijalba, J Romero, P Pesini, L Sarasa, I Monleon, I San-Jose, ... The journal of prevention of Alzheimer's disease 6, 34-41, 2019 | 71 | 2019 |
| Reliable measurements of the β-amyloid pool in blood could help in the early diagnosis of AD P Pesini, V Pérez-Grijalba, I Monleón, M Boada, L Tárraga, ... International Journal of Alzheimer’s Disease 2012, 2012 | 65 | 2012 |
| Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study V Pérez-Grijalba, J Arbizu, J Romero, E Prieto, P Pesini, L Sarasa, ... Alzheimer's research & therapy 11, 1-9, 2019 | 47 | 2019 |
| Blood amyloid beta levels in healthy, mild cognitive impairment and Alzheimer’s disease individuals: replication of diastolic blood pressure correlations and analysis of … A Ruiz, P Pesini, A Espinosa, V Pérez-Grijalba, S Valero, ... PLoS One 8 (11), e81334, 2013 | 47 | 2013 |
| Changes in the brain and plasma Aβ peptide levels with age and its relationship with cognitive impairment in the APPswe/PS1dE9 mouse model of Alzheimer’s disease M Izco, P Martinez, A Corrales, N Fandos, S Garcia, D Insua, M Montanes, ... Neuroscience 263, 269-279, 2014 | 45 | 2014 |
| Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI) I de Rojas, J Romero, O Rodriguez-Gomez, P Pesini, A Sanabria, ... Alzheimer's research & therapy 10, 1-12, 2018 | 44 | 2018 |
| Exploring APOE genotype effects on Alzheimer's disease risk and amyloid β burden in individuals with subjective cognitive decline: The FundacioACE Healthy … S Moreno–Grau, O Rodríguez‐Gómez, A Sanabria, A Pérez‐Cordón, ... Alzheimer's & Dementia 14 (5), 634-643, 2018 | 35 | 2018 |
| New insights into genetic variant spectrum and genotype–phenotype correlations of Rubinstein‐Taybi syndrome in 39 CREBBP‐positive patients V Pérez‐Grijalba, A García‐Oguiza, M López, J Armstrong, ... Molecular Genetics & Genomic Medicine 7 (11), e972, 2019 | 30 | 2019 |
| Validation of immunoassay-based tools for the comprehensive quantification of Aβ 40 and Aβ 42 peptides in plasma V Pérez-Grijalba, N Fandos, J Canudas, D Insua, D Casabona, ... Journal of Alzheimer's Disease 54 (2), 751-762, 2016 | 30 | 2016 |
| Longitudinal evaluation of the natural history of amyloid-β in plasma and brain SC Burnham, N Fandos, C Fowler, V Pérez-Grijalba, V Dore, JD Doecke, ... Brain communications 2 (1), fcaa041, 2020 | 28 | 2020 |
| Aβ 1-17 is a major amyloid-β fragment isoform in cerebrospinal fluid and blood with possible diagnostic value in Alzheimer's disease V Perez-Grijalba, P Pesini, JA Allué, L Sarasa, M Montanes, AM Lacosta, ... Journal of Alzheimer's Disease 43 (1), 47-56, 2015 | 24 | 2015 |
| Several direct and calculated biomarkers from the amyloid-β pool in blood are associated with an increased likelihood of suffering from mild cognitive impairment V Pérez-Grijalba, P Pesini, I Monleón, M Boada, L Tárraga, A Ruiz-Laza, ... Journal of Alzheimer's Disease 36 (1), 211-219, 2013 | 20 | 2013 |
| Optimized protocol for amyloid-β extraction from the brain M Izco, P Pesini, V Pérez-Grijalba, N Fandos, M Sarasa Journal of Alzheimer's Disease 34 (4), 835-839, 2013 | 16 | 2013 |
| Association between cell-bound blood amyloid-β (1-40) levels and hippocampus volume O Sotolongo-Grau, P Pesini, S Valero, A Lafuente, M Buendía, ... Alzheimer's research & therapy 6, 1-7, 2014 | 13 | 2014 |
| Outstanding phenotypic differences in the profile of amyloid-β between Tg2576 and APPswe/PS1dE9 transgenic mouse models of Alzheimer’s disease JA Allué, L Sarasa, M Izco, V Pérez-Grijalba, N Fandos, M Pascual-Lucas, ... Journal of Alzheimer's Disease 53 (3), 773-785, 2016 | 12 | 2016 |
| Safety, tolerability and immunogenicity of an active anti-Aβ (40) vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase … AM Lacosta, M Pascual-Lucas, P Pesini, D Casabona, V Pérez-Grijalba, ... | 10 | 2018 |
